Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma
Authors:
- Eric GrouzmannEGEric Grouzmann
- Laurence Drouard-TroalenLDLaurence Drouard-Troalen
- Eric BaudinEBEric Baudin
- Pierre-François PlouinPPPierre-François Plouin
- Beat MullerBMBeat Muller
- Daniela GrandDGDaniela Grand
- Thierry BuclinTBThierry Buclin
- 1 May 2010
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 162 (5) , 951-960
Abstract
Background: Plasma free and urinary metanephrines are recognized biomarkers for the assessment of pheochromocytoma. Plasma total metanephrines with a long half-life may represent another useful biomarker.Objective: The aim of this study is to evaluate the diagnostic performances of plasma total metanephrines alone or combined with free metanephrines and fractionated 24-h urinary metanephrines.Methods: A retrospective, case–control diagnostic test study was conducted between 1999 and 2007 in two university hospitals in Switzerland and two institutions in France. The patients included 46 cases with histologically proven pheochromocytoma, and 181 controls suspected of tumor with negative investigations and 3-year follow-up. None had renal dysfunction. Sensitivity and specificity were compared after expressing each measurement result as a ratio over its upper reference limit, adding the ratios of normetanephrine and metanephrine, and defining cut-off values of 1 or 2 for this sum.Results: Applying a cut-off value of 1, plasma free and total metanephrines and urinary fractionated metanephrines had similar sensitivities of 96% (95% confidence interval, 86–99%), 95% (85–99%), and 95% (84–99%) along with similar specificities of 89% (83–94%), 91% (84–95%), and 86% (80–91%). A cut-off of 2 for the sum of ratios over reference limit improves the specificity, and it can be used for a confirmation test based on another biomarker taken among the three biomarkers.Conclusion: All three metanephrine-based tests perform equivalently for diagnosing pheochromocytoma in the absence of renal insufficiency, and can be conveniently associated two by two for confirming/excluding tumor.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of Diagnostic Accuracy of Urinary Free Metanephrines, Vanillyl Mandelic Acid, and Catecholamines and Plasma Catecholamines for Diagnosis of PheochromocytomaThe Journal of Clinical Endocrinology & Metabolism, 2007
- Pheochromocytoma: recommendations for clinical practice from the First International SymposiumNature Clinical Practice Endocrinology & Metabolism, 2007
- Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?Clinical Chemistry, 2007
- Plasma metanephrines in renal failureKidney International, 2005
- A Comparison of Biochemical Tests for Pheochromocytoma: Measurement of Fractionated Plasma Metanephrines Compared with the Combination of 24-Hour Urinary Metanephrines and CatecholaminesThe Journal of Clinical Endocrinology & Metabolism, 2003
- Biochemical Diagnosis of PheochromocytomaJAMA, 2002
- The Effect of Disease-prevalence Adjustments on the Accuracy of a Logistic Prediction ModelMedical Decision Making, 1996
- Plasma Metanephrines in the Diagnosis of PheochromocytomaAnnals of Internal Medicine, 1995
- Measurement of Plasma Methoxyamines for the Diagnosis of PheochromocytomaHormone Research, 1991
- Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determinations.BMJ, 1981